Dry AMD webinar
Dry Age Related Macular Degeneration (dAMD) and geographic atrophy represent 85% of AMD, with no approved therapeutic options besides experimental cell therapy. To offer a new way to tackle […]
Dry Age Related Macular Degeneration (dAMD) and geographic atrophy represent 85% of AMD, with no approved therapeutic options besides experimental cell therapy. To offer a new way to tackle […]
Dry Age Related Macular Degeneration (dAMD) and geographic atrophy represent 85% of AMD, with no approved therapeutic options besides experimental cell therapy. To offer a new way to tackle […]